Getting Real or Keeping It Real?
By Business Review Editor
Pharma Deals Review: Vol 2007 Issue 89 (Table of Contents)
Published: 7 Nov-2007
DOI: 10.3833/pdr.v2007.i89.266 ISSN: 1756-7874
Section: General
Fulltext:
Abstract
The risk-adjusted or expected net present value (rNPV or eNPV) method combining decision-tree and discounted cash flow analysis is most frequently used for valuing pharma R&D projects and licensing deals...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.
Login Problems
RSS